News & Events
Work With Us Contact Us

HPTN083 Study

Tue 27 Feb 2018 Clinical Research

Title: A Phase 2b/3 Double Blind Safety and Efficacy Study of Injectable Cabotegravir Compared to Daily Oral Tenofovir Disoproxil Fumarate/Emtricitabine (TDF/FTC), for Pre-Exposure Prophylaxis in HIV-Uninfected Cisgender Men and Transgender Women who have Sex with Men
Status: Ongoing

What is HPTN083?
HPTN083 is a study being done to evaluate the efficacy of the long-acting injectable agent, cabotegravir (CAB LA), for pre-exposure prophylaxis (PrEP) in HIV-uninfected men and transgender women who have sex with men (MSM and TGW).

Who is participating in HPTN083 study?
HPTN083 will enroll 4,500 HIV-negative MSM and TGW, ages 18 and older at sites in the U.S., Argentina, Brazil, Peru, India, Thailand, Vietnam, and South Africa. The participants will be enrolled and followed up for up to 4.5 years.

Why is HPTN083 important?
If found to be safe and effective, the bi-monthly injectable CAB may be easier for some people to adhere to than current daily oral PrEP. The long-acting and accessible PrEP can potentially be offered as a choice of HIV prevention modalities for the most vulnerable population.